Literature DB >> 10515390

Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury.

W Chen1, C F Bennett, M E Wang, D Dragun, L Tian, K Stecker, J H Clark, B D Kahan, S M Stepkowski.   

Abstract

BACKGROUND: We have previously shown that phosphorothioate intercellular adhesion molecule (ICAM)-1 antisense oligodeoxynucleotide (oligo) IP-9125 blocks the expression of rat ICAM-1 mRNA in rat L2 cells. A single ex situ perfusion of grafts with unformulated IP-9125, suspended in Euro-Collins solution, prolonged the survival of kidney allografts in rats. The present experiments examined whether perfusion of kidneys with unformulated IP-9125 prevents ischemic/reperfusion injury.
METHODS: Kidneys were perfused ex situ with 2 ml of Euro-Collins solution without or with IP-9125 and exposed to 30-min cold (4 degrees C storage time) and 30-min warm (anastomosis time) ischemia. Kidneys were then transplanted to syngeneic nephrectomized recipients.
RESULTS: Within 24 hr after transplantation, the glomerular filtration rate values were reduced by almost 60% to 0.49+/-0.14 ml/min from 1.20+/-0.27 ml/min in normal kidneys (P<0.001). Kidney perfusion with 10 mg of either IP-12140 (0.41+/-0.07 ml/min) or IP-13944 (0.47+/-0.07 ml/min) control oligo was ineffective. In contrast, perfusion with 10 mg of IP-9125 significantly improved kidney function (0.8+/-0.18 ml/min; P<0.005), whereas the lower doses of 2 mg (0.47+/-0.13 ml/min; NS) or 4 mg (0.54+/-0.04 ml/min; NS) had no significant effect. The glomerular filtration rate results were confirmed by measurements of blood creatinine (CR) levels at 24 hr after grafting: untreated recipients had a twofold higher CR value (0.70+/-0.14 mg/dl) compared with normal controls (0.65+/-0.07 mg/dl; P<0.001). Although perfusion with 10 mg of control IP-12140 (0.80+/-0.14 mg/dl) or IP-13944 (0.65+/-0.07 mg/dl) did not affect CR levels, perfusion with 10 mg of IP-9125 (0.45+/-0.07 mg/dl) lowered CR levels. The Western blots or reverse transcription-polymerase chain reaction experiments performed in kidney transplants within 24 hr after grafting showed that 10 mg of IP-9125 (but not control IP-12140) reduced the expression of ICAM-1 protein and ICAM-1 mRNA, respectively.
CONCLUSIONS: Perfusion of grafts with unformulated ICAM-1 antisense oligo specifically reduces intragraft ICAM-1 protein expression and prevents ischemic/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515390     DOI: 10.1097/00007890-199909270-00022

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Current landscape for T-cell targeting in autoimmunity and transplantation.

Authors:  Daniel R Getts; Sushma Shankar; Emily M L Chastain; Aaron Martin; Meghann Teague Getts; Kathryn Wood; Stephen D Miller
Journal:  Immunotherapy       Date:  2011-07       Impact factor: 4.196

2.  Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys.

Authors:  Shinya Mizuno; Toshikazu Nakamura
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

3.  Preservation Solutions for Kidney Transplantation: History, Advances and Mechanisms.

Authors:  Yimeng Chen; Jian Shi; Terry C Xia; Renfang Xu; Xiaozhou He; Ying Xia
Journal:  Cell Transplant       Date:  2019-08-26       Impact factor: 4.064

Review 4.  RNA interference: a potent tool for gene-specific therapeutics.

Authors:  Thomas E Ichim; Mu Li; Hua Qian; Igor A Popov; Katarzyna Rycerz; Xiufen Zheng; David White; Robert Zhong; Wei-Ping Min
Journal:  Am J Transplant       Date:  2004-08       Impact factor: 8.086

5.  Renal Fibrosis Is Significantly Attenuated Following Targeted Disruption of Cd40 in Experimental Renal Ischemia.

Authors:  Shungang Zhang; Joshua D Breidenbach; Fatimah K Khalaf; Prabhatchandra R Dube; Chrysan J Mohammed; Apurva Lad; Stanislaw Stepkowski; Terry D Hinds; Sivarajan Kumarasamy; Andrew Kleinhenz; Jiang Tian; Deepak Malhotra; David J Kennedy; Christopher J Cooper; Steven T Haller
Journal:  J Am Heart Assoc       Date:  2020-03-21       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.